A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors

S. Deva, J-S. Lee, C-C. Lin, C-J. Yen, M. Millward, Y. Chao, B. Keam, M. Jameson, M-M. Hou, Y-K. Kang, B. Markman, C-H. Lu, K-M. Rau, K-H. Lee, L. Horvath, M. Friedlander, A. Hill, J. Wu, J. Hou, J. Desai

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

11 Citations (Web of Science)
Original languageEnglish
Number of pages2
JournalAnnals of Oncology
Volume29
DOIs
Publication statusPublished - Dec 2018
Externally publishedYes
EventESMO Immuno-Oncology Congress 2018 - Geneva, Switzerland
Duration: 13 Dec 201816 Dec 2018

Cite this